Incesu joined AstraZeneca in 2000 and assumed her current position in 2020, overseeing operations across the MEA, Türkiye and Pakistan. In 2025, regional revenues grew by 23%. In December 2025, AstraZeneca launched a cross-border, AI-driven MRI diagnostic initiative with MENACTRIMS and icometrix for the neuromyelitis optica spectrum disorder (NMOSD) across the Middle East and Africa.